A biocompatible bismuth based metal-organic framework as efficient light-sensitive drug carrier

Zhang, QY; Liu, YY; Wang, ZY; Wang, P; Zheng, ZK; Cheng, HF; Qin, XY; Zhang, XY; Dai, Y; Huang, BB

Abstract

The low toxicity and good photo active property endow bismuth based metal-organic frameworks (MOFs) potential candidates for efficient light-sensitive drug carrier. In this work, SU-101, composed of Bi and ellagic acid (EA), is found to display high ciprofloxacin (CIP) loading ratio (85.8%) and controlled CIP release under light illumination (the maximum CIP release ratio is 95.56%). Further investigations suggest that hydrogen bond between the C=O group in EA and the -OH group in CIP is responsible for above behavior. Light irradiation decreases the electron density around the C=O group in EA, which consequently leads to the broken of the hydrogen bond and therefore the release of CIP. Further investigations suggest that SU-101 is universal for other drugs, such as norfloxacin (NOR), amoxicillin (AMO), tetracycline (TET) and doxorubicin hydrochloride (DOX), since all of them can form hydrogen bond with SU-101. This work suggests that SU-101 holds great potential as efficient light-sensitive drug carrier, and the investigation of other Bi based MOFs as drug carrier is under investigation.(c) 2022 Elsevier Inc. All rights reserved.

Keywords: Drug carrier; Bismuth based metal-organic framework; Biocompatible materials; Controlled release

Related products/services

Metal-organic Frameworks (MOFs) Materials

Metal-Organic Frameworks (MOFs) have emerged as highly efficient carriers in light-sensitive drug delivery, representing a groundbreaking advancement in precision medicine. MOFs, crystalline structures composed of metal ions and organic ligands, offer a unique combination of porosity and tunable properties. In the realm of light-sensitive drug carriers, MOFs stand out for their ability to encapsulate photosensitive therapeutic agents within their well-defined pores. The controlled release of drugs is achieved through the strategic design of MOFs, allowing for precise responses to light stimuli. Photoresponsive MOFs enable spatiotemporal control over drug release, triggered by specific wavelengths of light. This light-sensitive drug delivery system holds immense promise for applications in targeted therapy, minimizing off-target effects and maximizing therapeutic efficacy.

For more product/services information, please contact us at:

Tel: (USA)

Tel: (Europe)

Fax:

Email: